Laboratory of Vaccine Research, Netherlands Vaccine Institute, Bilthoven, The Netherlands.
Virol J. 2010 Jun 2;7:114. doi: 10.1186/1743-422X-7-114.
Respiratory syncytial virus (RSV) is a primary cause of serious lower respiratory tract illness for which there is still no safe and effective vaccine available. Using reverse genetics, recombinant (r)RSV and an rRSV lacking the G gene (DeltaG) were constructed based on a clinical RSV isolate (strain 98-25147-X).
Growth of both recombinant viruses was equivalent to that of wild type virus in Vero cells, but was reduced in human epithelial cells like Hep-2. Replication in cotton rat lungs could not be detected for DeltaG, while rRSV was 100-fold attenuated compared to wild type virus. Upon single dose intranasal administration in cotton rats, both recombinant viruses developed high levels of neutralizing antibodies and conferred comparable long-lasting protection against RSV challenge; protection against replication in the lungs lasted at least 147 days and protection against pulmonary inflammation lasted at least 75 days.
Collectively, the data indicate that a single dose immunization with the highly attenuated DeltaG as well as the attenuated rRSV conferred long term protection in the cotton rat against subsequent RSV challenge, without inducing vaccine enhanced pathology. Since DeltaG is not likely to revert to a less attenuated phenotype, we plan to evaluate this deletion mutant further and to investigate its potential as a vaccine candidate against RSV infection.
呼吸道合胞病毒(RSV)是引起严重下呼吸道疾病的主要原因,目前尚无安全有效的疫苗。本研究利用反向遗传学技术,基于临床 RSV 分离株(株 98-25147-X)构建了重组 RSV(rRSV)和缺失 G 基因的 rRSV(DeltaG)。
两种重组病毒在 Vero 细胞中的生长与野生型病毒相当,但在 Hep-2 等人类上皮细胞中生长减少。DeltaG 在棉鼠肺中无法检测到复制,而 rRSV 与野生型病毒相比,衰减 100 倍。在棉鼠单次鼻腔内给药后,两种重组病毒均产生高水平的中和抗体,并对 RSV 攻击提供了相当持久的保护;对肺部的复制保护至少持续 147 天,对肺部炎症的保护至少持续 75 天。
综上所述,数据表明,单次剂量免疫高度衰减的 DeltaG 以及减毒的 rRSV,可在棉鼠中对随后的 RSV 攻击提供长期保护,而不会引起疫苗增强的病理学。由于 DeltaG 不太可能回复到减毒程度较低的表型,我们计划进一步评估这种缺失突变体,并研究其作为 RSV 感染疫苗候选物的潜力。